Zhejiang Xinguang Pharmaceutical Co Ltd

Zhejiang Xinguang Pharmaceutical Co Ltd maintains a strong liquidity position, as evidenced by a current ratio of 11.02, indicating that the company has significantly more current assets than current liabilities. The company's price-to-book ratio is 2.89, and the price-to-tangible-book ratio is also 2.89, suggesting that the market values the company's equity at nearly three times its book value. The enterprise value to revenue ratio is 51.0, which is relatively high, indicating that the company is trading at a premium relative to its revenue.

The company's profitability metrics are modest. The return on equity (ROE) is 0.0033, and the return on assets (ROA) is 0.003, both of which are below the typical thresholds for strong profitability in the pharmaceutical industry. The company's net income is 2,677,330 CNY, and its operating income is 2,374,440 CNY, which suggests that the company is generating positive earnings but at a relatively low margin.

Zhejiang Xinguang Pharmaceutical Co Ltd's revenue is concentrated in a single geographic market, primarily China. The company does not disclose specific segment details, but its revenue is derived from the sale of pharmaceutical products. The lack of geographic or product diversification may expose the company to higher concentration risk.

The company's growth trajectory is not clearly defined in the available data. The company's revenue for the latest period is 45,664,780 CNY, but there is no historical data provided to assess year-over-year growth. The company's capital expenditure is negative at -4,241,140 CNY, indicating that it is not investing in new assets, which may limit its long-term growth potential.

The company's risk profile includes a medium liquidity risk, as noted in the risk assessment. The company has a debt-to-equity ratio of 0.0, indicating that it is not leveraging debt to finance its operations. However, the company has a net cash position that is negative after subtracting total debt, which could be a concern if the company faces unexpected cash flow challenges.

There are no recent events or filings disclosed in the available data that would indicate significant changes in the company's operations or financial position. The company's financial statements do not mention any recent regulatory actions, product launches, or strategic partnerships that would impact its future performance.

Free cash flow surged 550.6% year-over-year to CNY 17.5 million, demonstrating significantly improved cash generation capabilities.

The company maintains a zero debt-to-equity ratio, ranking in the top quartile for financial leverage safety within its cohort.

Cash conversion efficiency is best-in-class at 10.13, vastly outperforming the cohort median of 0.95.

Operating income grew 13.0% year-over-year, showing resilience in core operational profitability despite flat revenue trends.

Revenue declined at a 4.6% compound annual growth rate over four years, signaling persistent top-line contraction.

The company faces medium liquidity risk, which could constrain financial flexibility during periods of market stress.